Exicure, Inc. (NASDAQ:XCUR) Sees Significant Drop in Short Interest

Exicure, Inc. (NASDAQ:XCUR) was the target of a significant drop in short interest in May. As of May 29th, there was short interest totaling 20,834 shares, a drop of 35.5% from the May 14th total of 32,290 shares. Based on an average daily volume of 14,468 shares, the short-interest ratio is currently 1.4 days. Approximately 0.7% of the company’s stock are sold short.

Exicure Stock Performance

Shares of NASDAQ XCUR opened at $2.79 on Tuesday. Exicure has a fifty-two week low of $2.62 and a fifty-two week high of $9.50. The company has a 50 day simple moving average of $3.31 and a two-hundred day simple moving average of $4.34. The company has a market capitalization of $17.77 million, a price-to-earnings ratio of -1.80 and a beta of 3.53.

Exicure (NASDAQ:XCUR) last announced its earnings results on Friday, May 29th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($18.60) by $18.31.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.